NHI · National Health Investors Inc
Substantial doubt about the company's ability to continue as a going concern.
“Bickford has been a cash basis tenant since 2022 when we received financial information from Bickford raising substantial doubt about its ability to continue as a going concern. As of June 30, 2026, these concerns had not been alleviated.”View the 10-Q filed Aug 10, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NHI
this stock
National Health Investors Inc
|
$3.45B | -7.9% | +12.1% | 20.3 | 4.6% |
|
WELL
Welltower Inc.
|
$166.33B | +26.9% | +35.6% | 117.2 | 2.6% |
|
VTR
Ventas, Inc.
|
$46.16B | +16.3% | +18.5% | 166.7 | 4.0% |
|
OHI
Omega Healthcare Investors Inc
|
$14.24B | +6.0% | +13.2% | 16.7 | 4.3% |
|
DOC
Healthpeak Properties, Inc.
|
$14.00B | +26.2% | +4.5% | 58.0 | 3.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NHI | -2.2% | -1.3% | -14.1% | -1.1% | -7.9% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -1.1% | +0.4% | -32.0% | -0.8% | -20.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.